Not every change has the same risk. A structured process evaluates potential impact on identity, quality, specification, documentation, supply continuity and customer commitments.
What procurement and laboratory teams should review
Classify the change and affected products or customers
Perform technical and quality risk assessment
Define comparability or requalification evidence
Communicate according to the approved agreement
Verify the scope behind every compliance term
COA, GMP, DMF, LOA, audit and quality agreement describe different evidence or responsibilities. Their relevance depends on the product, manufacturing stage, jurisdiction and buyer’s intended research or development pathway.
- Ask which legal entity, site, material and operation a claim covers.
- Verify confidential-file reference procedures separately from product release.
- Document outsourced roles, change notification and destination responsibilities.
Questions to resolve before quotation or release
- Which changes require prior customer approval?
- What comparability data will be available?
- How are emergency supply changes handled?
Repeat projects should establish a controlled baseline so future changes are visible rather than hidden inside the same SKU name.
Source material and further reading
This guide is informed by the following primary guidance and established technical resources. Always confirm the current version and its applicability to your material and jurisdiction.
HK PEPTIDES materials are supplied for laboratory research and documentation workflows only. They are not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.